Patients with bladder and bowel dysfunction. Neuromuscular dysfunction of bladder, unspecified
Conditions
Interventions
Intervention 1: Intervention group: the group receiving buspirone with a daily dose of 5 mg, 2 tablets daily. Intervention 2: Control group: control group with placebo (capsule containing sugar that l
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 15 Years
Inclusion criteria
Inclusion criteria: Have bladder and bowel dysfunction Between 6 and 15 years Do not have known problems of mental retardation, learning disorder or known psychiatric problems under treatment Do not have neurological problems Do not have an active urinary tract infection Do not have anatomical problems Be sponsored by the family
Exclusion criteria
Exclusion criteria: Have liver or kidney failure Have diabetes, high blood pressure, or heart abnormalities Take drugs that stimulate the urinary, cardiac, or psychological system Have known intestinal diseases5. Have a history of urinary, cardiac, or neurological surgeries
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effectiveness of buspirone as a single drug therapy for patients with urinary or fecal excretion disorders. Timepoint: Two and six months after receiving buspirone treatment. Method of measurement: Questionnaire, Euroflow, electromyography and urinary and intestinal excretion. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Akram Mirzaei
Tehran University of Medical Sciences
Outcome results
None listed